CRISPR Therapeutics Named to TIME 100 Most Influential Companies List

CRISPR Therapeutics AG (CRSP), a pioneering gene editing company, has attracted significant market attention with recent unusual options activity and a 30.9% stock price increase over the past month, outperforming the broader biomedical sector. The company is recognized for its revolutionary CRISPR/Cas9 technology and has expanded its therapeutic focus beyond sickle cell disease and beta-thalassemia to include cardiovascular and autoimmune diseases, highlighting a diverse pipeline and strategic partnerships such as with Vertex Pharmaceuticals. In 2025, CRISPR Therapeutics was named to TIME's 100 Most Influential Companies list in the Pioneers category, underscoring its innovation and impact in genetic medicine. Despite its market achievements and industry recognition, CRISPR Therapeutics is currently expected to post a loss per share, with earnings estimates remaining stable but negative for the current and next fiscal years. The company’s ongoing advancements and expansions in gene editing reflect a broader growth trend within the regenerative medicine and stem cell markets, which are projected to nearly double by 2030 amid increasing investments and technological breakthroughs. Investors and analysts view CRISPR as a leader in gene-based therapeutics with promising long-term potential despite short-term earnings challenges.